An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Dojolvi

Chemical Nametriheptanoin
Dosage FormLiquid (oral; 100% w/w of triheptanoin)
Drug ClassMiscellaneous
SystemDigestive
CompanyUltragenyx Pharm Inc
Approval Year2020

Indication

  • Indicated as a source of calories and fatty acids for the treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD).
Last updated on 12/9/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Dojolvi (triheptanoin) Prescribing Information.2020Ultragenyx Pharmaceutical Inc., Novato, CA
Document TitleYearSource
Effects of triheptanoin (UX007) in patients with long‐chain fatty acid oxidation disorders: Results from an open‐label, long‐term extension study.2020Journal of Inherited Metabolic Disease
Triheptanoin versus trioctanoin for long-chain fatty acid oxidation disorders: a double blinded, randomized controlled trial.2017Journal of Inherited Metabolic Disease
UX007 for the treatment of long chain-fatty acid oxidation disorders: Safety and efficacy in children and adults following 24 weeks of treatment.2017Molecular Genetics and Metabolism